The role of an aggrecan 32mer fragment in post-traumatic osteoarthritis
Abstract
Recommended to be brief (approx. 200 words) of the main findings during the reporting period. In this fourth reporting period, we successfully developed an assay to measure the aggrecan 32mer fragment in human and mouse serum. The 32mer has great potential as a novel biomarker for OA pain, as well as a target marker for aggrecanase activity. We have applied for a one-year no cost extension to further develop the assay, testing cohorts of existing human and mouse sera. Specifically, we will validate the use of plasma 32mer levels as markers for osteoarthritis (pain) in mice at different time points after DMM surgery, and this in wildtype as well as Chloe mice (as negative controls). In addition, we will continue to validate the assay in existing human sera.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1098671
Entities
People
- Amanda Fosang
- Anne-marie Malfait
Organizations
- University of Melbourne